Physician profile
Grace Song
NPI 1891870911
$738.10
in general payments reported to CMS, 2019-2025
15 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.75 · 2022: $80.59 · 2023: $357 · 2024: $140 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $639.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $638.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $178.89 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Exact Sciences Corporation | $94.38 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $78.16 | 2022-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $62.23 | 2023-2024 | Veozah, Myrbetriq |
| Baxter Healthcare | $44.14 | 2022 | |
| Pfizer INC. | $44.10 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $40.91 | 2023 | Gemtesa |
| Abbott Laboratories | $34.11 | 2023-2024 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $32.82 | 2023 | Quviviq |
| Currax Pharmaceuticals LLC | $29.20 | 2024 | Contrave |
| Abbvie INC. | $23.80 | 2023 | Ubrelvy |
| Sanofi Pasteur INC. | $22.39 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $20.45 | 2023 | Prehevbrio |
| Dexcom, INC. | $18.09 | 2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $14.43 | 2023 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Song listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.